Investor Presentation H1 2023
81
Investor presentation
First six months of 2023
Oral amycretin entered phase 1 in Q2 2022, combining protein.
and peptide expertise with oral technology
Amycretin is a GLP-1 and amylin receptor
co-agonist intended for oral delivery
Phase 1 single dose and multiple dose trial for
oral amycretin in obesity initiated in 2022
GLP-1 receptor
Novo NordiskⓇ
People
living with
Multiple ascending dose cohorts
overweight or
obesity, and
otherwise
Single ascending dose cohorts
healthy
Trial objectives
Amylin receptor
•
Assess the safety and tolerability of oral amycretin
•
Assess PK profile and explore PD effects
Utilising the SNAC technology
PK: Pharmacokinetics; PD: Pharmacodynamics
Trial initiation
•
Phase 1 was initiated in Q2 2022View entire presentation